US Lags In Vaccine Production

Too Little, Too Late?

According to informed sources, the US has a couple of million doses of a vaccine to mitigate the overall effects of the flu should a pandemic hit us within the next year or so. It will take until the end of the decade in order to stockpile something like 10 million doses.
Accordingly, that means at max, we'll be able to protect between 3 and 4% of the population compared to many western countries that are looking forward to protection between one third and one half or better of their populations....

Why the discrepancy? They got an earlier start and made protection a priority.

The Jury rests...

See the article below:
Source: American Society for Microbiology
Posted: February 18, 2006
New Influenza Vaccine Takes Weeks To Mass Produce
Using cell-based methods researchers have developed a commercially viable method for mass producing effective vaccines against potential pandemic influenza strains in weeks instead of the months required for traditional egg-based vaccines. They report their results today at the 2006 ASM Biodefense Research
The next flu pandemic could happen any time," says Keyang Wang, a scientist at Protein Sciences Corporation (PSC) and a researcher on the study. "The most effective method to control such an outbreak is the widespread use of a vaccine, preferably in a pro-active manner, so that the immune system is primed prior to actual virus exposure. The traditional egg-based method requires 3 to 6 months to develop the vaccine. With our cell-based method, as soon as the pandemic strain is identified, a matched vaccine can be massively produced within 4 weeks."
The vaccine strategy pursued by Protein Sciences, known commercially as FluBlok, uses a purified protein from the surface of the virus called hemagglutinin (the H part of a virus' designation, like H5N1 for the current avian influenza) to elicit an immune response to a specific strain of influenza. The protein is produced by first extracting the genes responsible for the production of hemagglutinin from the influenza virus and inserting them into a baculovirus. Specific host cells are then infected with the baculovirus and produce recombinant hemagglutinin (rHA). Phase II clinical trials show that rHA-based vaccines produced using this system are safe, elicit immunity equal to or greater than egg-based vaccines, and are 100% effective in the prevention of cell culture confirmed influenza.
Wang and his colleagues report the successful production of rHA from 4 strains of influenza that scientists believe to be likely the cause of the next pandemic (H5, H7, H9, and H2) at a level where manufacturing costs are expected to be equal to or less than that of traditional egg-based vaccines.
"It has been suggested that the next pandemic strain may be derived from H5, H7, H9 or H2 influenza viruses. The preparation of the recombinant baculoviruses for the production of these antigens and the successful purifications gives us a great advantage in fighting against a potential influenza pandemic, if it derived from any of these strains," says Wang. "Starting from a stocked recombinant baculovirus bank, a closely matched vaccine can be massively produced within 2 weeks."
PSC has recently signed a Letter of Intent which will support commercial scale manufacturing with the capacity to produce 6 Million doses of monovalent pandemic vaccine per week.
###
The American Society for Microbiology (ASM) is the largest single life science society, composed of over 42,000 scientists, teachers, physicians, and health professionals. Its mission is to promote research and training in the microbiological sciences and to assist communication between scientists, policymakers, and the public to improve health, economic well-being, and the environment.
Further information on the ASM Biodefense Research Meeting can be found online at www.asmbiodefense.org.